Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Liron Tuval-Kochen"'
Autor:
Michal Yalon, Liron Tuval-Kochen, David Castel, Itai Moshe, Inbal Mazal, Osher Cohen, Camila Avivi, Kineret Rosenblatt, Sarit Aviel-Ronen, Ginette Schiby, Joachim Yahalom, Ninette Amariglio, Raphael Pfeffer, Yaacov R Lawrence, Amos Toren, Gideon Rechavi, Shoshana Paglin
Publikováno v:
PLoS ONE, Vol 11, Iss 8, p e0161799 (2016)
[This corrects the article DOI: 10.1371/journal.pone.0155711.].
Externí odkaz:
https://doaj.org/article/53a6bd4b59a64f0c967b0678d62e1ce5
Autor:
Michal Yalon, Liron Tuval-Kochen, David Castel, Itai Moshe, Inbal Mazal, Osher Cohen, Camila Avivi, Kineret Rosenblatt, Sarit Aviel-Ronen, Ginette Schiby, Joachim Yahalom, Ninette Amariglio, Raphael Pfeffer, Yaacov Lawrence, Amos Toren, Gideon Rechavi, Shoshana Paglin
Publikováno v:
PLoS ONE, Vol 11, Iss 5, p e0155711 (2016)
Inhibitors of poly[ADP-ribose] polymerase 1 (PARPis) show promise for treatment of cancers which lack capacity for homologous recombination repair (HRR). However, new therapeutic strategies are required in order to overcome innate and acquired resist
Externí odkaz:
https://doaj.org/article/46c1ad8125414ba7817d1be1647f2e85
Autor:
Liron Tuval-Kochen, Shoshana Paglin, Gilmor Keshet, Yaniv Lerenthal, Charles Nakar, Tamar Golani, Amos Toren, Joachim Yahalom, Raphael Pfeffer, Yaacov Lawrence
Publikováno v:
PLoS ONE, Vol 8, Iss 10, p e77260 (2013)
In an effort to circumvent resistance to rapamycin--an mTOR inhibitor--we searched for novel rapamycin-downstream-targets that may be key players in the response of cancer cells to therapy. We found that rapamycin, at nM concentrations, increased pho
Externí odkaz:
https://doaj.org/article/6c3d31fd341b410abf82e84a0e38f2f4
Autor:
Shany Freedman, Ziv Versano, Moshe Leitner, Michal Yalon, Shoshana Paglin, Eitan Shany, Amos Toren, Liron Tuval-Kochen
Publikováno v:
Oncotarget. 9:27547-27563
Glioblastoma, a fatal disease in both adult and pediatric patients, currently has limited treatment options that offer no more than temporary relief. Our experiments with adult and pediatric glioblastoma cell lines showed that radiation induces a dos
Autor:
Liron Tuval-Kochen, Inbal Mazal, David Castel, Ginette Schiby, Joachim Yahalom, Shoshana Paglin, Osher Cohen, Itai Moshe, Ninette Amariglio, Raphael Pfeffer, Yaacov Richard Lawrence, Kineret Rosenblatt, Amos Toren, Sarit Aviel-Ronen, Gideon Rechavi, Camila Avivi, Michal Yalon
Publikováno v:
PLoS ONE
PLoS ONE, Vol 11, Iss 5, p e0155711 (2016)
PLoS ONE, Vol 11, Iss 5, p e0155711 (2016)
Inhibitors of poly[ADP-ribose] polymerase 1 (PARPis) show promise for treatment of cancers which lack capacity for homologous recombination repair (HRR). However, new therapeutic strategies are required in order to overcome innate and acquired resist
Autor:
Raphael Pfeffer, Joachim Yahalom, Yaniv Lerenthal, Shoshana Paglin, Tamar Golani, Amos Toren, Charles Nakar, Gilmor Keshet, Liron Tuval-Kochen, Yaacov Richard Lawrence
Publikováno v:
PLoS ONE, Vol 8, Iss 10, p e77260 (2013)
PLoS ONE
PLoS ONE
In an effort to circumvent resistance to rapamycin – an mTOR inhibitor - we searched for novel rapamycin-downstream-targets that may be key players in the response of cancer cells to therapy. We found that rapamycin, at nM concentrations, increased
Autor:
Ninette Amariglio, Raphael Pfeffer, Yaacov Richard Lawrence, Inbal Mazal, Kineret Rosenblatt, Amos Toren, Shoshana Paglin, Gideon Rechavi, Osher Cohen, Ginette Schiby, Joachim Yahalom, Itai Moshe, Michal Yalon, Sarit Aviel-Ronen, Liron Tuval-Kochen, Camila Avivi, David Castel
Publikováno v:
PLoS ONE
PLoS ONE, Vol 11, Iss 8, p e0161799 (2016)
PLoS ONE, Vol 11, Iss 8, p e0161799 (2016)
Inhibitors of poly[ADP-ribose] polymerase 1 (PARPis) show promise for treatment of cancers which lack capacity for homologous recombination repair (HRR). However, new therapeutic strategies are required in order to overcome innate and acquired resist